Together, we can act faster on Sepsis

Sepsis is a worldwide problem that can cause devastating patient consequences and incur significant healthcare costs. But diagnosing sepsis is challenging. Delays in diagnosing sepsis and initiating treatment result in increased symptom severity and patient risk, higher rates of long-term complications and mortality, and greater costs to healthcare systems.

Early sepsis detection improves patient prognosis and reduces the cost of sepsis-related care. Beckman Coulter is currently the only company providing all IVD testing modalities for sepsis diagnosis and management*^1

Sepsis, a public health problem: Clinical aspects and problems in the Identification

Most patients diagnosed with sepsis come from the hospital's emergency department, and their diagnosis remains challenging. In this white paper, Dr. Juan González del Castillo, Emergency Department in San Carlos Clinical Hospital, Madrid and coordinator of the Infections Group of the Spanish Society of Emergency Medicine, gives us a cross-sectional view of the importance of sepsis in epidemiological terms and healthcare costs. It brings us closer to the problem of managing sepsis in the emergency department and the solutions that are being implemented in these services to achieve a rapid identification of this syndrome.

Download the Whitepaper in the language of your preference.

Download the article

Using Monocyte Distribution Width to Improve Early Sepsis Detection

Adverse clinical outcomes and higher costs correlate to delays in the timing of sepsis interventions during the early phases of the syndrome. Due to this correlation, novel protocols and biomarkers are being studied to improve detection time.

This study compared the performance of MDW alone and in combination with white blood count, which is a commonly used clinical variable. The results showed that MDW is effective for sepsis recognition during an initial emergency department visit and adds value to early sepsis detection.

Download the article

Two‐center Comparison of Commercial PCT Immunoassays

In this study of fully automated procalcitonin immunoassays, Access PCT shows strong correlation and method concordance to the established method at key clinical decision points when used as an aid in diagnosing progression to severe sepsis or septic shock.

Download free paper

Whitepaper: The Role of Monocytes in the Progression of Sepsis

Cells of the innate immune system, such as monocytes and neutrophils, are the first-line of defense against infections. In the presence of sepsis, these cells produce a flood of inflammatory cytokines, causing widespread inflammation that can lead to death. Download the Whitepaper and learn more




Whitepaper*^2: Early Sepsis Detection: Reducing Mortality Rates and Hospital costs

Sepsis is a global problem in developed and resource-poor countries alike, and it is increasing at an annual rate of 1.5%, meaning that it is now killing more individuals than prostate cancer, breast cancer and HIV/AIDS combined*^3. Read more about how together, we can detect sepsis earlier; resulting in better patient prognosis and reduced cost*^4


On-Demand Webinar series

New: Septic and Non-septic States: The DxH 900 and the Role of MDW. Register here

New: Clinical performance of the new ESId hematological biomarker on the DxH 900 analyzer for the early detection of Septicemia (in French). Register here

Sepsis, a public health problem: Clinical aspects and problems in the Identification (In Spanish). Register here

Septic patient management in critical care units. New tools for early diagnosis (In Spanish). Register here

Science Behind Early Sepsis Indicator: Why do Monocytes Matter? Register here

Improved Detection of Sepsis in the Emergency Department with Early Sepsis Indicator: Register here

Infection and Sepsis Diagnostic Challenges for the Laboratories and Clinicians: Register here

Using Haematology Assays to Assess Sepsis Risk. Register here

Reducing Exposure to Antimicrobial Agents

Learn more about how the evaluation of our new procalcitonin assay allowed Portsmouth’s Queen Alexandra Hospital to explore ways to spearhead a new protocol for speeding up appropriate treatment within their hospital while placing particular emphasis on patient safety.


Strengthen Clinical Decision-making

The Early Sepsis Indicator uses the DxH series hematology analyzer's enhanced Coulter technology, which offers near native-state cellular characterization. The analyzer's powerful VCS 360 technology can uniquely detect morphological changes in monocytes, cells that play a role in the dysregulated immune response to sepsis. Identifying these monocyte morphological changes provides insight into possible sepsis earlier than other indicators.

Watch the video

ISLH Virtual Meeting


  • *^1:  
  • *^2:  For more information, download the Instructions for Use for the product.
  • *^3:
  • *^4:
    • Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive care medicine 2017;43:304-77
    • Jones SL et al. “Reductions in Sepsis Mortality and Costs After Design and Implementation of a Nurse-based Early Recognition and Response Program.” Jt Comm J Qual Patient Saf, vol. 41, no. 11. 2015, pp. 483–91.
    • Judd WR, Stephens DM, Kennedy DA. “Clinical and Economic Impact of a Quality Improvement Initiative to Enhance Early Recognition and Treatment of Sepsis.” Ann Pharmacol, vol. 48, no. 10. 2014, pp. 1269–75.


© 2020 Beckman Coulter, Inc. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. All other trademarks are the property of their respective owners.